Literature DB >> 3447533

Bacteriophage treatment of suppurative skin infections.

M Cisło1, M Dabrowski, B Weber-Dabrowska, A Woytoń.   

Abstract

The study material comprised 31 patients with chronic suppurative infections of the skin caused by Pseudomonas, Staphylococcus, Klebsiella, Proteus and Escherichia. Within 2-16 weeks of the treatment, an improvement of the general state was observed as well as suppression of the local inflammation, purification of a wound from the suppurative and necrotic content, faster healing of the ulcers and fully negative results of the bacteriologic tests. In 16 cases, an outstanding therapeutic effect was obtained, in 7 cases marked improvement was reported and in 2 a transitory improvement was reported. In 7 patients the treatment was abandoned due to the lack of improvement (1 case) or development of side effects (6 cases). The results obtained provide evidence for the high effectiveness of phage therapy in the treatment of suppurative skin infections.

Entities:  

Mesh:

Year:  1987        PMID: 3447533

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  14 in total

Review 1.  Bacteriophage therapy.

Authors:  A Sulakvelidze; Z Alavidze; J G Morris
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  Pharmacokinetic principles of bacteriophage therapy.

Authors:  Robert J H Payne; Vincent A A Jansen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis.

Authors:  John J Curtin; Rodney M Donlan
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms.

Authors:  G W Hanlon; S P Denyer; C J Olliff; L J Ibrahim
Journal:  Appl Environ Microbiol       Date:  2001-06       Impact factor: 4.792

5.  Phage treatment of human infections.

Authors:  Stephen T Abedon; Sarah J Kuhl; Bob G Blasdel; Elizabeth Martin Kutter
Journal:  Bacteriophage       Date:  2011-03

Review 6.  Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos.

Authors:  Mahdi Karimi; Hamed Mirshekari; Seyed Masoud Moosavi Basri; Sajad Bahrami; Mohsen Moghoofei; Michael R Hamblin
Journal:  Adv Drug Deliv Rev       Date:  2016-03-17       Impact factor: 15.470

7.  Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections.

Authors:  Sanjay Chhibber; Tarsem Kaur
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

8.  A phage-targeting strategy for the design of spatiotemporal drug delivery from grafted matrices.

Authors:  Ritsuko Sawada; Carrie Y Peterson; Ana Maria Gonzalez; Bruce M Potenza; Barbara Mueller; Raul Coimbra; Brian P Eliceiri; Andrew Baird
Journal:  Fibrogenesis Tissue Repair       Date:  2011-02-17

9.  Hydrolytic activity determination of Tail Tubular Protein A of Klebsiella pneumoniae bacteriophages towards saccharide substrates.

Authors:  Ewa Brzozowska; Anna Pyra; Krzysztof Pawlik; Monika Janik; Sabina Górska; Natalia Urbańska; Zuzanna Drulis-Kawa; Andrzej Gamian
Journal:  Sci Rep       Date:  2017-12-22       Impact factor: 4.379

10.  Genome analysis of the staphylococcal temperate phage DW2 and functional studies on the endolysin and tail hydrolase.

Authors:  Ruth Keary; Olivia McAuliffe; R Paul Ross; Colin Hill; Jim O'Mahony; Aidan Coffey
Journal:  Bacteriophage       Date:  2014-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.